Introduction
============

Calcium ion entry through presynaptic voltage-sensitive CaV2.2 calcium channels is known to gate transmitter release by the fusion and discharge of transmitter from docked synaptic vesicles (SVs) ([@B14]). The finding that SV fusion can be gated by a single CaV2.2 led to the prediction that the channel and SV are linked by at least one protein tether ([@B12]) and a number of studies have explored this molecular interaction. Two main molecular tethering linkage mechanisms have been considered; first, a link involving integral surface membrane proteins, in particular the SNARE protein syntaxin 1 ([@B11]; [@B10]; [@B8]) and a surface membrane-independent, cytoplasmic link from the channel directly to the SV ([@B6]; [@B17], [@B18]). A novel, cell-free synaptic vesicle-pull down assay (SV-PD) demonstrated for the first time that SVs can bind to CaV2.2 by a direct, membrane-independent mechanism ([@B17]). This study also showed that intact SVs can be captured by a synthetic fusion protein comprising the distal third (C3) of the CaV2.2 channel C-terminal ([@B17]). A later study used truncated or PDZ ligand domain-modified C3 constructs and mimetic blocking peptides to identify a 49 amino acid residue (aa) SV binding region, 9 aa proximal to the C-terminal distal tip ([@B18]), as indicated in **Figure [1](#F1){ref-type="fig"}**.

![**(A)** Diagram of the full-length C3 fusion proteins used in this study with the synaptic vesicle (SV) binding site and the synthetic mimetic peptides. GST-tagged fusion proteins, C3~WildF~ and C3~GST~, comprising approximately the distal third of the CaV2.2 C-terminal, are indicated by the horizontal dashed lines. The two fusion proteins are identical except for a FLAG tag on the distal tip of the former. The 49 aa sequence of the SV binding region is indicated together with the 9 aa (HEADEDDWC) channel terminus. The colored boxes define the five mimetic blocking peptides synthesized to identify the SV binding motif. The location of the HEADE peptide sequence is also indicated within the HEADEDDWC region (empty box). **(B)** Preliminary experiment showing inhibition of SV-PD by a mimetic peptide. Sucrose gradient-purified SV samples in a detergent-free buffer were pre-incubated with test HQARRVPNGY or HYTLGLNTGP peptides (1.2 mM) prior to SV-PD with immobilized C3~WildF~ fusion protein. SV capture was assessed by Western blotting (WB) for the recovery of at least two integral SV proteins: SV2 and STG. SV-PD was considerably less with HQARRVPNGY in comparison to HYTLGLNTGP. Equal loading of the fusion protein was confirmed using an anti-GST tag antibody. **(C)** Optimization of peptide concentration for detection of SV-PD block. Based on preliminary experiments, HQARRVPNGY (HQAR) was used to test for a suitable peptide concentration for effective block. SVs were pre-incubated with HQARRVPNGY peptide with a control peptide, SH3 (which was used as the control in all experiments, unless indicated), added in reciprocal amounts to maintain a total buffer peptide concentration of 1.2 mM (*N* = 1). SV-PD was carried out as described and SV capture was assayed by blot for SV2 or STG (not shown). Note the decline in SV2 recovery, corresponding to the reduction in SV capture, at HQARRVPNGY concentrations greater than 0.03 mM.](fncel-10-00145-g001){#F1}

In this study we used mimetic blocking peptides that span the SV binding region to search for specific SV attachment motifs. We then tested if these peptides would interfere with SV-PD by blocking the (unknown) SV binding site. In a complimentary study we also to tested if the peptides affected presynaptic SV recycling in functional isolated brain nerve terminals (synaptosomes, SSMs) using a 'peptide cryoloading' method combined with a styryl dye SV recycling assay ([@B9]). Finally, we used a combination of bioinformatics analysis comparing release site-associated CaV types in a range of species together with mutated peptide blockers to identify a putative SV binding motif.

Materials and Methods {#s1}
=====================

Synaptic Vesicle Binding Assays
-------------------------------

### Synaptosome and Synaptic Vesicle Fractionation

The synaptosome and SV fractionation method has been described in detail ([@B17]). Briefly, E14--E17 chick brains (typically 100 per preparation) were homogenized and the SVs purified by differential and sucrose density gradient centrifugation. The SVs were maintained intact in detergent-free buffer for all experiments. Key buffers were: homogenization buffer (HB), 0.32 M sucrose, 10 mM HEPES, 2 mM EDTA, pH 7.4; and HEPES-lysis buffer, 50 mM HEPES, 2 mM EDTA, pH 7.4 ([@B17], [@B18]).

### Antibodies

Antibodies used in the present study are listed in **Table [1](#T1){ref-type="table"}**.

###### 

Antibodies.

  Antibody            Target                                             Source (WB dilution)                   WB dilution
  ------------------- -------------------------------------------------- -------------------------------------- -------------
  FLAG (m)            FLAG tag                                           Sigma--Aldrich                         1:4000
  GST (m)             GST tag                                            Santa Cruz Biotechnology               1:4000
  L4569 (p)           C-terminal of CaV2.2 long splice variant           Stanley lab ([@B7])                    1:1000
  RIM2 (RIM1/2; p)    RIM (RIM1 and 2; RIM1/2)^∗^                        Synaptic Systems, GMBH                 1:2000
  SV2A (m)            SV2A (SV2)                                         Synaptic Systems, GMBH (clone 171G0)   1:1000
  Synaptotagmin (m)   Synaptotagmin-1 (STG)                              Abcam (clone ASV30)                    1:1000
  VAMP (p)            Vesicle Associated Membrane Protein 1,2,3 (VAMP)   Synaptic Systems, GMBH                 1:2000
  V-ATPase (p)        V-ATPase (V0) A1                                   Santa Cruz Biotechnology               1:1000
                                                                                                                

∗

RIM2 antibody has been characterized previously. See

Wong and Stanley (2010)

.

Western Blot
------------

Standard Western blotting (WB) method was carried out as described ([@B17], [@B18]) except immunoblots were imaged using a ChemiDoc^TM^ XRS System (Bio-Rad).

Protein Detection
-----------------

Mini-PROTEAN TGX 'Stain-Free' Precast Gels (4--15%, Bio-Rad) were used to C3WildF and C3HQless fusion protein dilution analysis. The samples were separated using SDS-PAGE as previously described ([@B17], [@B18]). The gels were than UV activated according to the manufacturer's protocol using the ChemiDoc XRS. The fusion protein bands were visualized within 0.5 s after gel activation.

Synaptic Vesicle Pull-Down Assay
--------------------------------

The SV-PD assay has been described in detail ([@B17], [@B18]). Briefly, purified SVs were incubated with immobilized C3 fusion proteins or GST control in a detergent free, SV-PD buffer (HB with 5 mM EGTA and free Ca^2+^ clamped to 10 nM, CaCl~2~ was calculated using MaxChelator). Prior to SV-PD, 40 μl of the SV suspension, containing the SV sample used for pull-down assays, was reserved for WB. SV-PD samples were washed four times with SV-PD buffer and solubilized in 4X Laemmli sample buffer with 5% β-mercaptoethanol for WB. Immunoblots were probed for integral SV membrane proteins as markers for vesicle capture. SV-PD was considered positive if the band intensity of two of the vesicle integral membrane marker proteins, generally SV2 and STG, were more intense than for control samples ([@B17], [@B18]). The use of freshly prepared SVs and detergent-free buffers makes these both time-demanding experiments with some non-specific SV capture with control beads and fusion proteins ([@B18]). Criteria for acceptance for further analysis were stringent based on a rejection of blots with a significant level of non-specific binding to controls.

CaV2.2 Distal C-terminal Region Mimetic Peptides
------------------------------------------------

Control and putative blocking peptides were synthesized at the SPARC BioCentre (Toronto, ON). Control peptides for this study have been described ([@B18]): RQLPQTPL (SH3, aa 2210--2217), HEADEDDWC (aa 2349--2357), and HEADE (aa 2349--2353). Five peptides spanning the SV binding site region were: ATNSGRSSRT (aa 2299--2308), SYVSSLTSQS (aa 2309--2318), HQARRVPNGY (aa 2319--2328), HYTLGLNTGP (aa 2329--2338), and GTGTRGRSYY (aa 2339--2348; **Figure [1A](#F1){ref-type="fig"}**). Peptides were reconstituted in HB at 10 mM. SVs were incubated with the peptides for 2 h at 4°C prior to pull-down with the fusion proteins. To establish a suitable peptide concentration, we carried out SV-PD trials using C3~WildF~ in the presence of HQARRVPNGY, which was shown to block in preliminary experiments (**Figure [1B](#F1){ref-type="fig"}**). To avoid complications due to variations in total soluble peptide we included a control peptide, SH3, or HEADE, to maintain the total peptide concentration at 1.2 mM. Previous experiments demonstrated that neither of these inhibit SV-PD ([@B17]). In a preliminary experiment we found that 50% maximal inhibition of SV-PD was observed at ∼0.3 mM, as assessed by SV2 recovery, with both control peptides (SH3, **Figure [1C](#F1){ref-type="fig"}**; HEADE *Data not shown*) and we therefore used a 0.6 mM peptide for all blocking experiments, except as stated. During the course of these experiments we noted that one of the control peptides, HEADE, a sequence within the C-terminal distal to our primary area of interest, actually enhances SV-PD (**Figures [2](#F2){ref-type="fig"}** and **[3](#F3){ref-type="fig"}**). This effect was not observed with the SH3 or HEADEDDWC -- a C-terminal tip peptide that includes HEADE (**Figure [3](#F3){ref-type="fig"}**). Thus, while this finding is of interest in itself, the latter makes it less likely that enhancement in SV-PD observed with HEADE is of biological significance. Nonetheless, after this finding we stopped using HEADE as a control in the peptide-block experiments.

![**(A)** Effect of the mimetic blocking peptides on SV-PD with C3~WildF~. Purified SVs were pre-treated with each of the five mimetic blocking peptides or HEADE and SH3 controls (0.6 mM) prior to SV-PD with C3~WildF~ fusion protein. SV-PD was assessed by the vesicle marker proteins, SV2 and STG. We also blotted for two additional integral proteins, V-ATPase and VAMP. Compared to the SH3 peptide control, integral SV protein band intensities were reduced by HQARRVPNGY and GTGTRGRSYY, increased by HEADE and minimally affected by ATNSGRSSRT, SYVSSLTSQS, or HYTLGLNTGP. Protein bands were faint with a purified GST control. C3~WildF~ fusion protein was identified by either anti-FLAG or anti-CaV2.2 (L4569) antibodies. **(B)** Quantification of mimetic peptide effect on SV-PD. SV2 and STG protein band intensities were normalized to the SH3 control peptide on the same immunoblot. Column graphs of SV2 (top) and STG (bottom) show percent mean ± SE of *N* separate experiments. HQARRVPNGY (*N* = 8) and GTGTRGRSYY (*N* = 5) peptides inhibited SV capture as indicated by both vesicle marker proteins (SV2, top; STG, bottom). SYVSSLTSQS shows a large variability between experiments due to a single outlier; if omitted the mean was 118 ± 35%. HEADE peptide resulted in a significant enhancement in the mean SV2 band intensity (SYVSSLTSQS *N* = 5; HEADE, *N* = 6). *t*-test, ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001.](fncel-10-00145-g002){#F2}

![**HQARRVPNGY inhibits SV-PD with native C3 fusion protein.** **(A)** The effect of HQARRVPNGY on SV capture as in **Figure [2](#F2){ref-type="fig"}** was repeated using C3~GST~ probing for SV2 and STG (0.6 mM peptide). **(B)** The peptide inhibited SV-PD compared to SH3 peptide whereas three control peptides, a zero peptide control and also one other test peptide, HYTLGLNTGP, had no effect. Both SV2 and STG exhibited increased mean band intensities with HEADE but this did not reach statistical significance (*t*-test, *p* \> 0.1) while HEADEDDWC was unchanged. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01.](fncel-10-00145-g003){#F3}

We also generated a series of blocking peptides to zero in on the C3 region SV binding motif. These peptides were: HQARRAPNGA, HQARRGPNGG, HQARRAGGGA, HQARR GAAAG, HQARRAAAAA, HQAAAVPNGY, HQAGGAGGGA, AAARRVPNGY, and GGARRAGGGA (see below).

Immunoblot Quantification and Analysis
--------------------------------------

Immunoblots were probed for integral vesicle proteins, SV2, and STG, which were used as markers for SV capture in this study. Immunoblots were imaged with the ChemiDoc (Bio-Rad) with a broad range of exposure times. For each experiment, protein band intensities were quantified by densitometry using Image Lab (Bio-Rad) software from a common blot at a single exposure selected for clear bands without saturation. Background counts were subtracted using an automated routine and protein band intensities of test (*I*~x~) or control (*I*~c~) peptide treatments were measured. Percent integral protein capture, and hence %SV-PD, was calculated as: (*I*~x~/*I*~c~) × 100.

All experiments were pre-hoc testing treated samples to a defined control. Data are presented as mean [+]{.ul}SE (%) and "*N*-value" represents the number of independent experiments. Statistical analysis was performed with GraphPad Prism 6.0. Each peptide treatment was tested using a one sample, two-tailed *t*-test based on the null hypothesis that mean SV-PD = 100% (that is equal to the control peptide), as described ([@B17]). Data was also tested with a *post hoc* ANOVA adjusted with a Bonferroni--Holms correction for multiple comparisons^[1](#fn01){ref-type="fn"}^. Values were considered significantly different if *p* \< 0.05.

Functional Assay of Synaptic Vesicle Recycling
----------------------------------------------

### Cryoloading

The method has been described ([@B9]). Briefly, SSMs were isolated as described above. SSMs were pelleted in SET buffer (0.32 M sucrose; 1 mM EDTA; 5 mM Tris) in preparation for cryoloading. 1.2 mM of the blinded mimetic peptide (or equivalent control) was added to the SSM mixture (50 μL total volume) with 20 μM of the 3 kD Dextran-FITC loading maker and was frozen slowly in a --80° freezer.

### Styryl Dye Uptake

Vesicle turnover was assessed using a standard dye uptake method ([@B9]). Briefly, thawed SSMs were plated in Krebs-like physiological buffer (KPB: 143 mM NaCl, 4.7 mM KCl, 1.3 mM MgSO~4~, 1.2 mM CaCl~2~, 20 mM HEPES, 0.1 mM NaH~2~PO~4~, 10 mM glucose; pH 7.4) and depolarized for 2 min at 30°C using 40 mM K^+^ in the presence of 1 μM FM4-64 (Invitrogen). SSMs were washed with KPB supplemented with 1 mM Advasep-7 (Sigma--Aldrich) prior to mounting in DAKO mounting medium (DAKO) for fluorescence imaging.

### Microscopy

Imaging was carried out on a Zeiss Axioplan2 with a 63×, 1.4 NA objective.

Ethics Statement
----------------

Only chick embryos were used in this study. The University Health Network TG&W Animal Care Committee has granted a waiver to perform these experiments as the embryos used in this study were all in early stages of embryonic development and before day 21 and therefore committee review and approval was not necessary. However, the study was reviewed by a veterinarian and the euthanasia procedure was validated.

Peptide Mimetic Blocker Experimental Design and Analysis
--------------------------------------------------------

The experiment and data analysis were carried out blind. A laboratory member unconnected with the SV recycling experiment assigned an alphabet code to each test peptide and the code was broken on completion of analysis. The styryl dye uptake quantification method has been described ([@B9]). Briefly, a minimum of three images per treatment per experimental trial were quantified. Cryoloaded single SSMs were identified by positive stain for the loading marker (FITC-dextran) and were imaged by bright field to ensure isolation from un-loaded neighbors. Each FITC-stained SSM was scored as FM4-64 positive or negative by eye and the ratio of positive over total examined was used to calculate the percentage of SV recycling SSMs.

The fraction of dextran-positive control SSMs that showed styryl dye uptake was consistent between experimental trials and across treatments (no-load, 61.3 ± 3.2; HEADEDDWC 59.5 ± 1.6) and hence, normalization was not necessary. Student's *t*-test was used to compare test peptide-treated to both the No-load and HEADEDDWC peptide controls.

Results
=======

SV Binding Assay, Bait Proteins, and C-terminal Mimetic Blocking Peptides
-------------------------------------------------------------------------

### The SV-PD Assay

We have described a cell-free assay, termed SV-PD, to test if SVs can be captured by the intact CaV2.2 channel. Briefly, fresh SVs are purified by differential centrifugation on discontinuous sucrose gradients for each experiment. The SVs are then incubated with an immobilized bait, in the present case the distal third of the channel C-terminal (C3 region), in a detergent-free buffer. Successful SV capture is assessed by Western blot for integral SV proteins (SV2, STG, VAMP, etc).

### CaV2.2 distal C-terminal Fusion Proteins

Most of these experiments were carried out using the *N*-terminal-GST-tagged fusion protein, C3~wildF~ (**Figure [1A](#F1){ref-type="fig"}**), as the bait. C3~wildF~ fusion protein is identical to the chick C-terminal C3 region except for the addition of a FLAG tag to the C-terminal tip ([@B18]) and was used for most of this study. We also generated a new fusion protein, C3~GST~ (**Figure [1A](#F1){ref-type="fig"}**, see below) which is identical to the native C-terminal but differs from C3~wildF~ by the absence of the FLAG tag. Both fusion proteins were purified with high yield by our bacterial expression system and were robust for SV-PD.

### Blocking Peptides

To further restrict the SV attachment site within the previously identified 49 aa region of the C3 terminal region we synthesized five abutting 10 aa mimetic blocking peptides (**Figure [1A](#F1){ref-type="fig"}**). Beginning from the N terminal end these were: ATNSGRSSRT, SYVSSLTSQS, HQARRVPNGY, HYTLGLNTGP, and GTGTRGRSYY. The peptide blockers were designed to be non-overlapping to permit their use in combinations while minimizing complication due to mutual binding interference.

### Effect of Single Mimetic Peptides on SV-PD

#### A subset of the SV binding region mimetic peptides inhibited SV-PD

To identify which segment of the SV binding region plays a role in SV binding we carried out SV-PD experiments in the presence of each of the five peptides separately (**Figure [2A](#F2){ref-type="fig"}**). SV2 and STG bands were quantified by densitometry (**Figure [2B](#F2){ref-type="fig"}**) and normalized to a control SH3 peptide-treated band.

The results with SV2 and STG were comparable but the immunoblot signal-to-noise ratio was higher with the former. The blots showed that SV-PD was not significantly inhibited by ATNSGRSSRT, SYVSSLTSQS (which exhibited large variability), or HYTLGLNTGP. However, it was reduced significantly by HQARRVPNGY (*p* \< 0.001) and by GTGTRGRSYY (*p* \< 0.01; **Figure [2B](#F2){ref-type="fig"}**).

### HQARRVPNGY Inhibits SV Capture with Native C3 Fusion Protein

The fusion protein used in the above studies, C3~WildF~ is identical to the native, long splice chick CaV2.2 aa sequence but with a FLAG tag on its terminus. To increase confidence in our results and to rule out the remote possibility that the FLAG tag introduced anomalous results we repeated the experiment with C3~GST~ which lacks this tag. This fusion protein also captured SVs, as assessed by SV-PD (**Figure [3A](#F3){ref-type="fig"}**) and, consistent with the findings with C3~WildF~, this was markedly inhibited by HQARRVPNGY but not by another binding region peptide, HYTLGLNTGP, as compared to no-peptide or SH3 (**Figure [3B](#F3){ref-type="fig"}**). Compared to the no-peptide or SH3 controls, the mean SV-PD was higher with HEADE and HYTLGLNTGP, but neither reached significance (*p* \> 0.1 for both SV2 and STG). No significant effect was observed with the HEADEDDWC control peptide (*p* \> 0.1).

### SV Recycling Is Inhibited by Single Peptides

We used cryoloading/styrlyl dye uptake ([@B9]) to test if the effect observed in the cell-free SV-PD assay predicts the effect of the peptide blockers on SV recycling in intact synaptosomes. Test and control peptides were cryoloaded into the SSMs together with an inert fluorescent dextran marker. The fraction of individual dextran-positive SSMs that recycled SVs was assayed by styryl dye uptake (**Figure [4A](#F4){ref-type="fig"}**), as described ([@B9]; [@B18]). A blinded protocol was used: the investigator carrying out the peptide loading and imaging was unaware of the treatments until after each experiment was completed and analyzed.

![**Effect of mimetic peptides on SV recycling.** SSMs were cryoloaded in a blinded manner with the indicated peptides (1.2 mM) together with 3 kD Dextran-FITC (20 μM). The cryoloaded terminals were depolarized with 40 mM K^+^ in the presence of 1.2 mM Ca^2+^ to trigger exocytosis and uptake of FM4-64 (1 μM) by vesicle turnover. The ***FITC*** panels show SSMs that have been cryoloaded with the loading marker and the ***FM4-64*** panels show SSMs that have taken up styryl dye. ***Blue circles*** indicate SSMs that are peptide loaded, as indicated by the loading marker, and are also positive for FM4-64. ***Green circles*** indicate SSMs that have been cryoloaded but fail to take up FM4-64. The ***red circle*** indicates an SSM that was not cryoloaded but was able to take up FM4-64. **(B)** Histogram of percent ± SE of dextran-positive SSMs that were FM4-64 positive from four experiments. Statistical test to the dextran-only control and HEADEDDWC, respectively, for each treatment are indicated as: *t*-test, ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01. Analysis by ANOVA (Bonferroni--Holm) confirmed a reduction in dye-uptake with HQARRVPNGY (*p* \<\< 0.01).](fncel-10-00145-g004){#F4}

Styryl dye uptake was indistinguishable between the dextran-only controls and with the control peptide HEADEDDWC and also several of the test peptides, including ATNSGRSSRT, SYVSSLTSQS, and GTGTRGRSYY. A significant, but moderate reduction was observed with HYTLGLNTGP (*p* \< 0.02). However, HQARRVPNGY caused a marked, ∼55% reduction (compared to untreated control) in dye-positive SSMs (*p* \< 0.001; **Figure [4B](#F4){ref-type="fig"}**).

### Peptide Combinations

We carried out a number of pilot experiments to test if SV-PD or styryl dye uptake could be further inhibited using various combination of the five mimetic peptides. However, since none of the combinations tested resulted in qualitatively greater effect than with the HQARRVPNGY peptide alone we presume that the primary SV binding site is within this 10 aa stretch.

### Peptide Blockers and the Capture of the SV Accessory Protein RIM1/2

The effect of the peptide blockers and controls on SV-PD was generally consistent regardless of which SV integral membrane protein was used as the SV capture indicator. There has been considerable interest in the role of RIM1/2 in SV recruitment and hence, we also blotted for this protein in our SV-PD experiments. As reported previously ([@B19]), RIM1/2 protein bands detected by Western blot of the SVs were typically not intense (**Figure [5A](#F5){ref-type="fig"}**). Interestingly, the mimetic peptide generated a different pattern of RIM1/2 recovery than for the integral SV proteins, as detailed above. Using C3~WildF~ as the bait protein, RIM1/2 was detected in the presence of all test or control peptides (**Figure [5A](#F5){ref-type="fig"}**). Densitometry analysis of two high-molecular weight bands in the RIM ladder (1 and 2 in **Figure [5A](#F5){ref-type="fig"}**) failed to demonstrate inhibition by HQARRVPNGY (**Figure [5B](#F5){ref-type="fig"}**). The mean intensity was lower in the presence of GTGTRGRSYY peptide but this failed to reach statistical significance (0.1 \> *p* \> 0.05). The C3~GST~ fusion protein (**Figure [1A](#F1){ref-type="fig"}**), that lacks the distal FLAG tag and is identical to the native protein gave very similar results (data not shown).

![**Synaptic vesicle accessory protein RIM1/2 recovery is not blocked by HQARRVPNGY.** **(A)** As in **Figure [3](#F3){ref-type="fig"}**, purified SVs were treated with blocking or control peptides (0.6 mM each) followed by SV-PD with C3~WildF~. SH3 peptide was used as a control. As above, HQARRVPNGY markedly inhibited SV capture compared to controls as indicated in the SV2 immunoblot. GST + SH3 control lane shows protein capture in the absence of the C3-FLAG protein. **(B)** Mean [+]{.ul} SE RIM1/2 higher (band \#1, *upper histogram*) and lower (band \#2, *lower histogram*) molecular weight band intensities were normalized to the SH3 control from the same experiment and plotted and were analyzed as in **Figure [2](#F2){ref-type="fig"}**. HQARRVPNGY had no significant effect on RIM1/2 capture as assessed by protein band intensity 1 or 2 (*as labeled*). Lower mean RIM1/2 intensities were observed with GTGTRGRSYY for both quantified bands but this failed to reach statistical significance (*t*-test, 0.1 \> *p* \> 0.05).](fncel-10-00145-g005){#F5}

### The HQARRVPNGY Region is Necessary for Effective SV Capture by the C3 Region

The peptide block experiments above identify the HQARRVPNGY region as containing the binding site for the SV onto the distal C-terminal. To rule out the possibility that the peptide might interfere with SV-PD by an anomalous mechanism we created a new GST fusion protein, C3~HQless~, that was identical to C3~WildF~ which lacks HQARRVPNGY (**Figure [6A](#F6){ref-type="fig"}**). Western blots of the C3~HQless~ fusion protein probed with FLAG (*not shown*) or anti-CaV2.2 C-terminal tip (L4569) antibody exhibited bands with a molecular weight that was, as expected, slightly lower than for C3~WildF~ (**Figure [6B](#F6){ref-type="fig"}**). SV-PD was markedly reduced (*N* = 3) using C3~HQless~ as the bait in comparison with C3~WildF~ (**Figure [6B](#F6){ref-type="fig"}**), providing independent support for the conclusion that HQARRVPNGY contains a key C3 region SV binding aa sequence. This region is the focus of the rest of this study though the residual SV-PD may indicate a secondary binding site. Further studies will be necessary to determine if there is any significant residual SV binding by the rest of the C3 region.

![**Deletion of HQARRVPNGY from the C-terminal C3 region greatly reduces SV capture.** **(A)** A GST-tagged C3 fusion protein, C3~HQless~, was generated that was identical to C3~WildF~ but without the HQARRVPNGY sequence. **(B)** The molecular weight of the GST-C3~HQless~ band was confirmed by identification in a Western blot by both anti-GST (on the N terminal end, data not shown) and L4569, the antibody directed against the distal tip of the CaV2.2 C-terminal (beyond the deleted region). SV-PD was markedly reduced with C3~HQless~ compared to C3~WildF~. In the blot shown the concentration of C3~HQless~ was equal or higher than that of C3~WildF~, as demonstrated in a two-step method. First, we used L4569 to identify the protein band corresponding to each fusion protein. Since these bands were saturated in the blot, even with very short exposures, they could not be used for quantification. However, we also identified protein bands using a 'Stain-free' method and these bands were not saturated. Based on the L4569 probe we quantified the fusion protein bands by densitometry to obtain a C3~WildF~/C3~HQless~ ratio of 0.81. Thus, the SV2 bands were far darker with C3~WildF~ despite a lower concentration of the fusion protein. Similar results were observed in two additional experiments.](fncel-10-00145-g006){#F6}

### Identification of the HQARRVPNGY Binding Motif: Bioinformatics Analysis

Alignment of chick, rat and human CaV2.2 C-terminal sequences identified the conserved aa residues HxxRRVPNGY (**Figure [7A](#F7){ref-type="fig"}**), or HxxRRΦPNGY, where Φ is a hydrophobic residue. Since CaV2.1 channels are also important for transmitter release at fast transmitting terminals we extended the analysis to this channel type (note: chick CaV2.1 has not been cloned). This reduced the highly conserved region to RRΦPNGY, and served as our candidate binding motif.

![**The HQARRVPNGY peptide region is conserved across fast-transmission presynaptic calcium channel types.** Each panel shows an alignment of the chick CaV2.2 distal C3 region, as examined in this study, with the indicated CaV channel types from chick, rat, and human (*as available*). **(A)** CaV2.1 and CaV2.2. The five mimetic peptides (corresponding to chick CaV2.2) are indicated under the alignment. **(B)** CaV2.3. **(C)** CaV1.3. **(D)** CaV1.4. The HQARRVPNGY peptide sequence is indicated by the dashed box in each panel. ^∗^Distal aa extends beyond the diagram. Numbers above each set reflect the aligned protein set (including gaps), and do not correspond to any individual channel type.](fncel-10-00145-g007){#F7}

### Identification of the HQARRVPNGY Binding Motif: Blocking Peptide Analysis

To gain further insight into the SV binding site we created an additional series of blocking peptides in which amino acid residues of interest were mutated and tested with SV-PD (**Figures [8A--C](#F8){ref-type="fig"}**). SH3 or zero peptide, and HQARRVPNGY itself were used as negative and positive controls, respectively. Analysis focused on SV2 recovery but across the experiment STG recovery correlated strongly (*r* = 0.977, *p* \< \< 0.01)

![**Blocking peptide analysis of the SV binding motif.** **(A)** and **(B)** SV-PD assessed by immunoblot for SV integral membrane proteins in the presence of a range of HQARRVPNGY mutant peptides. SH3 and HQARRVPNGY served as negative and positive controls, respectively. **(C)**. SV2 bands densitometry histograms normalized to SH3. *N* = number of separate experiments. Values are means ± SE. Means were tested for significance from 100%: *t*-test, ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001. The data was also analyzed using by *post hoc* ANOVA, correcting for multiple comparisons (Bonferroni and Holm). The significance levels were similar: 0 peptide *p* \> 0.05; HQARRVPNGY *p* \< 0.01, HQARRAPNGA *p* \< 0.01, HQARRGPNGG *p* \< 0.05, AAARRVPNGY *p* \> 0.05, GGARRAGGGA *p* \> 0.05, HQARRAGGGA *p* \< 0.05, HQARRGAAAG *p* \< 0.01, HQARRAAAAA *p* \< 0.05, HQAAAVPNGY *p* \> 0.05, and HQAGGAGGGA *p* \> 0.05. Note, however, that SV2 capture with AARRVPNGY and GGARRAGGGA peptides was reduced significantly with the *t*-test but not the ANOVA analysis.](fncel-10-00145-g008){#F8}

Substitution of the two hydrophobic aa (Φ), V and Y, with A or G (HQARR[A]{.ul}PNG[A]{.ul}, HQARR[G]{.ul}PNG[G]{.ul}; **Figures [8A--C](#F8){ref-type="fig"}**) had no effect on block. Interestingly, and to our surprise, neither did substitution of the entire highly conserved ΦPNGY sequence HQARR[AGGGA]{.ul} and HQARR[GAAAG]{.ul} (**Figures [8B,C](#F8){ref-type="fig"}**). This result contradicted our bioinformatics-based hypothetical ΦPNGY-based SV-binding motif. We therefore turned our attention to the first five aa of HQARRVPNGY. Mutation of the arginine pair with either A or G (HQA[AA]{.ul}VPNGY, HQA[GG]{.ul}AGGGA; **Figures [8A--C](#F8){ref-type="fig"}**) eliminated inhibition of SV-PD, suggesting that these are essential. However, this aa pair was not sufficient for the full effect, because SV-PD inhibition was also reduced by replacement of the first two aa, HQ ([AA]{.ul}ARRVPNGY, [GG]{.ul}ARRAGGGA; **Figures [8A--C](#F8){ref-type="fig"}**). Without HQ the mean SV2 recovery was significantly less than 100% with both peptides, based on a *t*-test analysis but significance was not reached using ANOVA. Thus, our data is at least suggestive that the RR pair can cause a partial inhibition of SV-PD. In summary, our analysis identified the RR aa pair as essential for SV capture and this was enhanced by HQ.

Discussion
==========

The objective of this study was to identify an SV binding site within a 49 aa region of the distal C-terminal as reported earlier ([@B18]). We report first, that a 10 aa peptide, HQARRVPNGY, markedly inhibited SV capture using two different distal C3 region fusion proteins and also inhibited SV recycling, as assessed by depolarization-triggered styryl dye uptake. Within the HQARRVPNGY sequence we find that the HxxRR motif is required for effective SV capture by the channel C3 region.

Most of the experimental techniques and materials used in this study have been validated previously including fractionation, purification and characterization of SSMs and SVs ([@B5]; [@B17], [@B18]\]; the SV-PD assay ([@B17]) and the peptide-cryoloading method combined with styryl dye assessment of SV recycling ([@B9]). Three fusion proteins were used. C3~WildF~ was reported previously ([@B18]) while C3~GST~, a new bait that lacks the terminal FLAG tag, is identical to the previously reported C3~Strep~ ([@B18]) but is tagged with GST to make it comparable with our other constructs. We also constructed C3~HQless~, which is identical to C3~WildF~ but with an excised HQARRVPNGY region.

In a previous study we reported that the distal tip peptide HEADEDDWC or its proximal segment, HEADE, did not inhibit SV-PD. We therefore assumed that we could use HEADE as a peptide control. To our surprise this peptide increased SV-PD, as confirmed by comparison to the SH3 peptide \[that also did not inhibit SV-PD previously ([@B18])\] as well as all the inactive peptides used in this study (**Figures [2B](#F2){ref-type="fig"}**, **[3B](#F3){ref-type="fig"}**, and **[8](#F8){ref-type="fig"}**). This result might indicate that there is a region in the C-terminal that acts as an 'on'-switch for binding. However, the failure to detect a similar enhancement with the overlapping, but longer HEADEDDWC peptide raises a question as to whether this has biological significance and will be explored in a future study.

Out of the five mimetic blocking peptides spanning the 49 aa binding site only HQARRVPNGY reliably and effectively inhibited SV-PD. A smaller effect was, however, also observed with GTGTRGRSYY. Of these two, only the former showed evidence of functional inhibition of SV recycling, supporting the hypothesis that this binding site has biological significance. We have not explored the role of GTGTRGRSYY further but the lack of functional inhibition with this peptide in the synaptosome cryoloading experiments combined with the marked reduction in SV-PD observed with C3~HQless~, which retains GTGTRGRSYY, suggests that its role is of less significance than that of the HQARRVPNGY region. A moderate reduction in styryl dye uptake was also observed with HYTLGLNTGP. Since this peptide had no detectable effect on SV-PD, we suppose that it interferes with an unrelated molecular interaction during SV recycling.

We used the SV-PD/peptide block strategy to carry out a systematic analysis of the binding site aa sequence (**Figure [8](#F8){ref-type="fig"}**). To our surprise, the ^∗^PNGY region could be mutated without any obvious loss of SV capture. However, removal of the arginine pair eliminated SV-PD. Interestingly, inhibition of SV-PD by the RR pair was markedly reduced, but not eliminated if HQ was also mutated. Since HQ could not capture SVs in the absence of the arginine pair we conclude that it plays a facilitatory role in SV binding.

The HxxRR motif is conserved in CaV2.2 channels from chick to human, consistent with a significant biological role (**Figure [7A](#F7){ref-type="fig"}**) and the RR pair can be traced at least as far back as to fish (**Figure [9](#F9){ref-type="fig"}**). Interestingly, in the other principal release site-associated calcium channel, CaV2.1, the arginine pair is retained but the Hxx is replaced with an RHxRR (**Figure [7A](#F7){ref-type="fig"}**) in which the positive charge is not only retained but enhanced and may serve the same binding function.

![**Evolutionary conservation of the SV binding motif in early vertebrates.** Alignment of the region encompassing the chick CaV2.2 HQARR sequence for species from chick (yellow highlight) to fish. Positively charged aa are indicated in red. ^\#^Sequence predicted by GenBank software but not cloned.](fncel-10-00145-g009){#F9}

Alignment of CaV2.3 channels, which can also support transmitter release at fast synapses, with CaV2.2 failed to identify any of the HxxRR elements (**Figure [7B](#F7){ref-type="fig"}**), raising a question as to how these channels may bind SVs. However, further scrutiny reveals a downstream H\#RRRR(R) (**Figure [7B](#F7){ref-type="fig"}**) which might serve the same function. The more distantly related CaV1.3/CaV1.4, which gate transmitter release at sensory cell synapses ([@B15]; [@B2]; [@B3]), such as at the higher vertebrate auditory hair cell, lack the HxxRR motif (**Figures [7C,D](#F7){ref-type="fig"}**). The motif is also absent in *Drosophila* CaV2.2-like channels (data not shown). Interestingly, both the sensory cell and *Drosophila* synapses exhibit a release site-associated structure, a ribbon in the former and T-bar in the latter, that is absent from fast transmitting synapses. Perhaps these structures usurp the SV binding site on the C-terminal. It is possible, therefore, that the SV binding site is specific for SV recycling at classical, fast transmitting release sites and that it evolved at an earlier stage during the diversification of CaV2 types ([@B1]).

As expected, since they are all components of the same SVs, integral SV proteins were recovered in parallel in SV-PD experiments -- thus, enhancement or inhibition of one such protein was mirrored by an equal enhancement or inhibition of its partner integral protein ([@B18]). However, immunoblot bands for the SV-associated protein RIM1/2 were faint and did not vary in parallel with the integral proteins (**Figure [5](#F5){ref-type="fig"}**). Thus, RIM1/2 capture was not reduced significantly by HQARRVPNGY nor was it enhanced by HEADE, supporting the hypothesis that RIM1/2 interacts with the channel C3 region by a mechanism that somehow differs from that with the integral SV proteins ([@B18]). A number of previous reports have failed to demonstrate RIM1/2 co-immunoprecipitation with the full-length CaV2.2 ([@B4]; [@B7]; [@B19]), arguing against a common stable complex. However, co-variance of the channel and RIM1/2 at the intact transmitter release site does support the idea that the two proteins are components of separate interacting molecular complexes ([@B7]). How RIM1/2 can be isolated with the purified SVs and yet fail to act in accord with the other SV proteins remains a mystery that will be the subject of further study.

This study does not address at which stage the C-terminal HxxRR contributes to SV recycling nor does it identify its putative SV binding partner. The length of the C-terminal and lack of predicted structure make it less attractive as a mechanism to bring the SV within range of the CaV calcium nanodomain ([@B18]; [@B13]), at least without additional molecular partners. We have recently speculated that this binding region may play a role in delivering the SV to the release site, serving to capture the vesicle from the surrounding cytoplasm ([@B18]; [@B13]) while additional and subsequent molecular interactions determine the precise molecular arrangement required for nanodomain-based release gating ([@B16]; [@B18]).
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